Shenzhen YHLO Biotech CoSHSE:688575 +0.66%64 Piotroski F-Score is 6 as of Jul. 02, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates SHSE:688575 with a GF Score™ of 64/100 and a GF Value™ of ¥14.47 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 807 Medical Devices & Instruments companies, Shenzhen YHLO Biotech Co ranks better than 81.16% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Shenzhen YHLO Biotech Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Shenzhen YHLO Biotech Co's Piotroski F-Score or its related term are showing as below:
SHSE:688575'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 5 Max: 6
Current: 6
During the past 9 years, the highest Piotroski F-Score of Shenzhen YHLO Biotech Co was 6. The lowest was 3. And the median was 5.
Shenzhen YHLO Biotech Co (SHSE:688575) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Shenzhen YHLO Biotech Co Piotroski F-Score Related Terms
Shenzhen YHLO Biotech Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688575 vs ABT, SYK, MDT: Piotroski F-Score Comparison
For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen YHLO Biotech Co Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Shenzhen YHLO Biotech Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Shenzhen YHLO Biotech Co's current Net Income (TTM) was 31.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Shenzhen YHLO Biotech Co's current Cash Flow from Operations (TTM) was 506.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Shenzhen YHLO Biotech Co's return on assets of this year was 0.00719415. Shenzhen YHLO Biotech Co's return on assets of last year was 0.06360185.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Shenzhen YHLO Biotech Co's gearing of this year was 0.13950287. Shenzhen YHLO Biotech Co's gearing of last year was 0.14398911.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Shenzhen YHLO Biotech Co's current ratio of this year was 2.19430353. Shenzhen YHLO Biotech Co's current ratio of last year was 2.12377429.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Shenzhen YHLO Biotech Co's number of shares in issue this year was 598.356. Shenzhen YHLO Biotech Co's number of shares in issue last year was 507.4.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Shenzhen YHLO Biotech Co's gross margin of this year was 0.65525603. Shenzhen YHLO Biotech Co's gross margin of last year was 0.6469932.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Shenzhen YHLO Biotech Co's asset turnover of this year was 0.41363105. Shenzhen YHLO Biotech Co's asset turnover of last year was 0.51734087.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
1
+
1
+
0
+
1
+
0
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Shenzhen YHLO Biotech Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Shenzhen YHLO Biotech Co (SHSE:688575) has a Piotroski F-Score of 6 as of Jul. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shenzhen YHLO Biotech Co and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Shenzhen YHLO Biotech Co's Piotroski F-Score has ranged from 3.00 to 6.00. According to the industry distribution chart, Shenzhen YHLO Biotech Co ranks #152 out of 807 companies in the Medical Devices & Instruments industry, placing it in the top 18.8%.
Is Shenzhen YHLO Biotech Co's Piotroski F-Score too high?
Shenzhen YHLO Biotech Co's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Shenzhen YHLO Biotech Co's value of 6 is 20% above this industry median. Based on the distribution chart, Shenzhen YHLO Biotech Co ranks #152 out of 807 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shenzhen YHLO Biotech Co ranks #152 out of 807 companies for Piotroski F-Score. This places Shenzhen YHLO Biotech Co in the top 19% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Shenzhen YHLO Biotech Co's value of 6 is 20% above this benchmark. Historically, Shenzhen YHLO Biotech Co's own Piotroski F-Score has ranged from 3.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Shenzhen YHLO Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen YHLO Biotech Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shenzhen YHLO Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen YHLO Biotech Co's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.47, compared to a current price of ¥9.17 — trading 36.6% below its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Medical Devices & Instruments industry median of 5.00. Shenzhen YHLO Biotech Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current Piotroski F-Score is 6 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued.
The current stock price of ¥9.17 is trading 36.6% below its estimated GF Value™ of ¥14.47.
GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688575:
Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
GF Value™: ¥14.47 vs. price of ¥9.17 (36.6% below fair value)
Industry Position: 20% above the Medical Devices & Instruments median (#152 of 807)
No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
64GF Score
Get the complete analysis for SHSE:688575
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688575 has been successfully added to your 
